Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis

Clinical Reviews in Allergy and Immunology

Volumn 41, Issue 3, 2011, Pages 282-295

  Elias, Peter M ^a,b   Wakefield, Joan S ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial peptides; Atopic dermatitis; Barrier function; Barrier repair

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CERAMIDE; CHOLESTEROL; CHOLESTEROL SULFATE; CYCLOSPORIN; DERMATOLOGICAL AGENT; DESONIDE; EPICERAM; FATTY ACID; FILAGGRIN; FILAMENT AGGREGATING PROTEIN; FLUTICASONE PROPIONATE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; KALLIKREIN; KALLIKREIN 5; LIVER X RECEPTOR AGONIST; LYMPHOEPITHELIAL KAZAL TYPE INHIBITOR; PHOSPHOLIPID; PIMECROLIMUS; PROTEIN; SECRETORY PHOSPHOLIPASE A2; SERINE PROTEINASE INHIBITOR; SPHINGOMYELIN; STEROID; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; ANGIOSARCOMA; ANTIMICROBIAL BARRIER; ARTICLE; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BASAL CELL CARCINOMA; CELL NUCLEUS; CELLULAR DISTRIBUTION; CORNEOCYTE; CYTOPLASM; CYTOSOL; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRY SKIN; ECZEMA; ESOPHAGUS METASTASIS; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL INFECTION; GENE DOSAGE; HEPATOBLASTOMA; HUMAN; ICHTHYOSIS VULGARIS; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI VARICELLIFORM ERUPTION; KERATINOCYTE; LAMELLAR BODY; LOSS OF FUNCTION MUTATION; LYMPH NODE; LYMPH VESSEL; LYMPHOMA; MAINTENANCE THERAPY; MALASSEZIA DERMATITIS; MELANOMA; MENTAL STRESS; MOLLUSCUM CONTAGIOSUM; NETHERTON DISEASE; NONHUMAN; OFF LABEL DRUG USE; PAGET NIPPLE DISEASE; PATHOGENESIS; PERMEABILITY BARRIER; PH; PRESCRIPTION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RESPIRATORY TRACT INFECTION; ROSACEA; SEBORRHEIC DERMATITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BARRIER FUNCTION; SKIN CANCER; SKIN CELL; SKIN FLORA; SKIN FUNCTION; SKIN INFLAMMATION; SKIN WATER LOSS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STEROID THERAPY; STRATUM CORNEUM; STREPTOCOCCUS INFECTION; SWEAT GLAND TUMOR; SYSTEMIC THERAPY; TH2 CELL; TINEA CORPORIS; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERMEDIATE FILAMENT PROTEINS; SKIN; STRESS, PHYSIOLOGICAL;

EID: 80054887636     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8231-1     Document Type: Article

References (118)

1. JL Sugarman JW Fluhr AJ Fowler, et al. 2003 The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease Arch Dermatol 139 1417 1422 14623701 10.1001/archderm.139. 11.1417 (Pubitemid 37433131)
2. S Seidenari G Giusti 1995 Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin Acta Derm Venereol 75 429 433 8651017 1:STN:280:DyaK283jslSksw%3D%3D (Pubitemid 26051887)
3. E Proksch R Folster-Holst JM Jensen 2006 Skin barrier function, epidermal proliferation and differentiation in eczema J Dermatol Sci 43 159 169 16887338 1:CAS:528:DC%2BD28XotVCkt7g%3D 10.1016/j.jdermsci.2006.06.003 (Pubitemid 44189201)
4. SL Chamlin J Kao IJ Frieden, et al. 2002 Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity J Am Acad Dermatol 47 198 208 12140465 10.1067/mjd.2002.124617
5. BS Baker 2006 The role of microorganisms in atopic dermatitis Clin Exp Immunol 144 1 9 16542358 1:CAS:528:DC%2BD28Xks1Cnsbg%3D 10.1111/j.1365-2249. 2005.02980.x
6. PM Elias LC Wood KR Feingold 1999 Epidermal pathogenesis of inflammatory dermatoses Am J Contact Dermat 10 119 126 10444104 1:STN:280: DyaK1MzntlCmsw%3D%3D 10.1016/S1046-199X(99)90054-4 (Pubitemid 29416060)
7. PM Elias KR Feingold 2001 Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications Arch Dermatol 137 1079 1081 11493102 1:STN:280:DC%2BD3MrjvFGisQ%3D%3D (Pubitemid 32756467)
8. A Taieb 1999 Hypothesis: from epidermal barrier dysfunction to atopic disorders Contact Dermat 41 177 180 1:STN:280:DyaK1MvktlWitA%3D%3D 10.1111/j.1600-0536.1999.tb06125.x (Pubitemid 29427906)
9. R Grimalt V Mengeaud F Cambazard 2007 The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study Dermatology 214 61 67 17191050 1:CAS:528:DC%2BD28XhtlCktLjF 10.1159/000096915 (Pubitemid 46033003)
10. PM Elias 2005 Stratum corneum defensive functions: an integrated view J Invest Dermatol 125 183 200 16098026 1:CAS:528:DC%2BD2MXntlCrtrk%3D (Pubitemid 41648149)
11. PM Elias 2007 The skin barrier as an innate immune element Sem Immunopath 29 3 14 10.1007/s00281-007-0060-9 (Pubitemid 47596384)
12. M Denda M Nakatani K Ikeyama M Tsutsumi S Denda 2007 Epidermal keratinocytes as the forefront of the sensory system Exp Dermatol 16 157 161 17286806 1:CAS:528:DC%2BD2sXjvFWmurw%3D 10.1111/j.1600-0625.2006.00529.x (Pubitemid 46242956)
13. C Caubet N Jonca M Brattsand, et al. 2004 Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7 J Invest Dermatol 122 1235 1244 15140227 1:CAS:528: DC%2BD2cXkvVOrurY%3D 10.1111/j.0022-202X.2004.22512.x (Pubitemid 38651099)
14. M Brattsand K Stefansson C Lundh Y Haasum T Egelrud 2005 A proteolytic cascade of kallikreins in the stratum corneum J Invest Dermatol 124 198 203 15654974 1:CAS:528:DC%2BD2MXnvFCrtw%3D%3D 10.1111/j.0022-202X.2004.23547.x (Pubitemid 40100969)
15. MH Braff A Di Nardo RL Gallo 2005 Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies J Invest Dermatol 124 394 400 15675959 1:CAS:528:DC%2BD2MXhsVKmsr4%3D 10.1111/j.0022-202X.2004.23443.x (Pubitemid 40175887)
16. A Oren T Ganz L Liu T Meerloo 2003 In human epidermis, beta-defensin 2 is packaged in lamellar bodies Exp Mol Pathol 74 180 182 12710950 1:CAS:528:DC%2BD3sXjtFWmsLk%3D 10.1016/S0014-4800(02)00023-0 (Pubitemid 36438667)
17. PG Fallon T Sasaki A Sandilands, et al. 2009 A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming Nat Genet 41 602 608 19349982 1:CAS:528:DC%2BD1MXktVKgur8%3D 10.1038/ng.358
18. TC Scharschmidt MQ Man Y Hatano, et al. 2009 Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens J Allergy Clin Immunol 124 496 506 19733297 1:CAS:528:DC%2BD1MXhtV2kurnJ 10.1016/j.jaci.2009.06.046 506.e1-6
19. M Schmuth D Crumrine RB Presland, et al. 2005 Basis for the epidermal functional abnormalities in granular layer-absent (AGL) vs. -present (PGL) ichthyosis vulgaris J Invest Dermatol 124 A72
20. H Ohman A Vahlquist 1994 In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis Acta Derm Venereol 74 375 379 7817676 1:STN:280:DyaK2M7hslChug%3D%3D (Pubitemid 24305854)
21. JP Hachem MQ Man D Crumrine, et al. 2005 Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity J Invest Dermatol 125 510 520 16117792 1:CAS:528:DC%2BD2MXhtVersbnK 10.1111/j.0022-202X.2005.23838.x
22. M Demerjian JP Hachem E Tschachler, et al. 2008 Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2 Am J Pathol 172 86 97 18156206 1:CAS:528:DC%2BD1cXhslOmtb0%3D 10.2353/ajpath.2008.070161 (Pubitemid 351186371)
23. A Briot C Deraison M Lacroix, et al. 2009 Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome J Exp Med 206 1135 1147 19414552 1:CAS:528:DC%2BD1MXlvVGmu74%3D 10.1084/jem.20082242
24. AD Irvine WH McLean 2006 Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis J Invest Dermatol 126 1200 1202 16702964 1:CAS:528:DC%2BD28Xls1GhsL0%3D 10.1038/sj.jid.5700365 (Pubitemid 43997892)
25. TJ Hudson 2006 Skin barrier function and allergic risk Nat Genet 38 399 400 16570058 1:CAS:528:DC%2BD28XivFShtr0%3D 10.1038/ng0406-399
26. P Fleckman S Brumbaugh 2002 Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris Exp Dermatol 11 327 336 12190941 10.1034/j.1600-0625.2002. 110406.x (Pubitemid 36934663)
27. MD Howell BE Kim P Gao, et al. 2007 Cytokine modulation of atopic dermatitis filaggrin skin expression J Allergy Clin Immunol 120 150 155 17512043 1:CAS:528:DC%2BD2sXntF2msrg%3D 10.1016/j.jaci.2007.04.031 (Pubitemid 46990506)
28. T Bieber 2008 Atopic dermatitis N Engl J Med 358 1483 1494 18385500 1:CAS:528:DC%2BD1cXktlSgt7c%3D 10.1056/NEJMra074081 (Pubitemid 351482740)
29. GM O'Regan A Sandilands WH McLean AD Irvine 2008 Filaggrin in atopic dermatitis J Allergy Clin Immunol 122 689 693 18774165 10.1016/j.jaci.2008.08. 002 1:CAS:528:DC%2BD1cXht1Siu7jP
30. A Sandilands FJ Smith AD Irvine WH McLean 2007 Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis J Invest Dermatol 127 1282 1284 17502856 1:CAS:528:DC%2BD2sXlt1aqsLk%3D 10.1038/sj.jid.5700876 (Pubitemid 46763004)
31. AM Lynley BA Dale 1983 The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein Biochim Biophys Acta 744 28 35 6187370 1:CAS:528:DyaL3sXhslGitb4%3D 10.1016/0167-4838(83)90336-9 (Pubitemid 13101039)
32. CR Harding IR Scott 1983 Histidine-rich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation J Mol Biol 170 651 673 6195345 1:CAS:528:DyaL2cXitVynsA%3D%3D 10.1016/S0022-2836(83)80126-0 (Pubitemid 14241851)
33. P Fleckman BA Dale KA Holbrook 1985 Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes J Invest Dermatol 85 507 512 3905974 1:CAS:528:DyaL2MXmtFWqsrY%3D 10.1111/1523-1747. ep12277306 (Pubitemid 16204221)
34. M Takahashi T Tezuka N Katunuma 1996 Filaggrin linker segment peptide and cystatin alpha are parts of a complex of the cornified envelope of epidermis Arch Biochem Biophys 329 123 126 8619628 1:CAS:528:DyaK28XisFGlurk%3D 10.1006/abbi.1996.0199 (Pubitemid 26143405)
35. PM Steinert LN Marekov 1995 The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope J Biol Chem 270 17702 17711 7543090 1:CAS:528:DyaK2MXnt1CrtrY%3D 10.1074/jbc.270.30.17702
36. IR Scott CR Harding JG Barrett 1982 Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum Biochim Biophys Acta 719 110 117 7171620 1:CAS:528:DyaL38XlvFKhtbc%3D (Pubitemid 13223076)
37. AV Rawlings IR Scott CR Harding PA Bowser 1994 Stratum corneum moisturization at the molecular level J Invest Dermatol 103 731 741 7963664 1:STN:280:DyaK2M%2Flt1Ortw%3D%3D 10.1111/1523-1747.ep12398620
38. IR Scott CR Harding 1986 Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment Dev Biol 115 84 92 3516761 1:CAS:528: DyaL28XktVCis7k%3D 10.1016/0012-1606(86)90230-7 (Pubitemid 16118872)
39. T Abe M Ohkido K Yamamoto 1978 Studies on skin surface barrier functions:-skin surface lipids and transepidermal water loss in atopic skin during childhood J Dermatol 5 223 229 361786 1:STN:280:DyaE1M%2FkvV2jtw%3D%3D (Pubitemid 9065277)
40. Y Werner M Lindberg 1985 Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis Acta Derm Venereol 65 102 105 2408409 1:STN:280:DyaL2M3itFaruw%3D%3D (Pubitemid 15144831)
41. M Fartasch TL Diepgen 1992 The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol Suppl (Stockh) 176 26 31 1:STN:280: DyaK3s7hvVCguw%3D%3D
42. T Hubiche C Ged A Benard, et al. 2007 Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort Acta Derm Venereol 87 499 505 17989887 1:CAS:528:DC%2BD1cXotlKkug%3D%3D 10.2340/00015555-0329 (Pubitemid 351373393)
43. Elias P, Williams M, Crumrine D, Schmuth M (2010) Disorders of cornification (the ichthyoses): key clinical features, biochemical genetics, cellular pathogenesis, and diagnostic ultrastructure. In: Current problems in dermatology. Karger, Basel, p 110
44. T Scharschmidt Y Hatano M Man, et al. 2008 Mice with deficiency in epidermal filaggrin display heightened susceptibility to hapten-induced atopic dermatitis J Instr Dev 128 S92
45. P Krien M Kermici 2000 Evidence for the existence of a self-regulated enzymatic process within human stratum corneum-an unexpected role for urocanic acid J Invest Dermatol 115 414 420 10951277 1:CAS:528:DC%2BD3cXmsFWht7o%3D 10.1046/j.1523-1747.2000.00083.x
46. E Sprecher S Chavanas JJ DiGiovanna, et al. 2001 The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis J Invest Dermatol 117 179 187 11511292 1:CAS:528:DC%2BD3MXmvVOqu78%3D 10.1046/j.1523-1747.2001.01389.x (Pubitemid 34205699)
47. E Nylander-Lundqvist O Back T Egelrud 1996 IL-1 beta activation in human epidermis J Immunol 157 1699 1704 8759758 1:CAS:528:DyaK28XkvFWgs7c%3D (Pubitemid 126449113)
48. PM Elias 1996 Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers Exp Dermatol 5 191 201 8889466 1:STN:280:DyaK2s%2FksVeqtw%3D%3D 10.1111/j.1600-0625.1996.tb00117.x (Pubitemid 26316184)
49. T Roelandt B Thys C Heughebaert, et al. 2009 LEKTI-1 in sickness and in health Int J Cosmet Sci 31 247 254 19467033 1:CAS:528:DC%2BD1MXpvFyms74%3D 10.1111/j.1468-2494.2009.00516.x
50. AJ Walley S Chavanas MF Moffatt, et al. 2001 Gene polymorphism in Netherton and common atopic disease Nat Genet 29 175 178 11544479 1:CAS:528:DC%2BD3MXnsFKgur0%3D 10.1038/ng728 (Pubitemid 32952654)
51. Y Vasilopoulos MJ Cork R Murphy, et al. 2004 Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis J Invest Dermatol 123 62 66 15191543 1:CAS:528:DC%2BD2cXlslWhsb4%3D 10.1111/j.0022-202X.2004.22708.x (Pubitemid 38833464)
52. S Weidinger H Baurecht S Wagenpfeil, et al. 2008 Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk J Allergy Clin Immunol 122 560-8 e4 18774391
53. JP Hachem D Crumrine J Fluhr, et al. 2003 pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion J Invest Dermatol 121 345 353 12880427 1:CAS:528:DC%2BD3sXmsVansL4%3D 10.1046/j.1523-1747.2003.12365.x (Pubitemid 36969909)
54. A Di Nardo P Wertz A Giannetti S Seidenari 1998 Ceramide and cholesterol composition of the skin of patients with atopic dermatitis Acta Derm Venereol 78 27 30 9498022 10.1080/00015559850135788 (Pubitemid 28103674)
55. G Imokawa A Abe K Jin, et al. 1991 Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 96 523 526 2007790 1:STN:280:DyaK3M7nvVejtw%3D%3D 10.1111/1523-1747.ep12470233
56. JP Hachem F Wagberg M Schmuth, et al. 2006 Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome J Invest Dermatol 126 1609 1621 16601670 1:CAS:528:DC%2BD28Xls1Khu78%3D 10.1038/sj.jid.5700288
57. JP Hachem E Houben D Crumrine, et al. 2006 Serine protease signaling of epidermal permeability barrier homeostasis J Invest Dermatol 126 2074 2086 16691196 1:CAS:528:DC%2BD28XotFCjurg%3D 10.1038/sj.jid.5700351
58. MQ Man GD Barish M Schmuth, et al. 2008 Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation J Invest Dermatol 128 370 377 17713572 1:CAS:528:DC%2BD2sXhsVSksbvN 10.1038/sj.jid.5701011 (Pubitemid 350249387)
59. PG Sator JB Schmidt H Honigsmann 2003 Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis J Am Acad Dermatol 48 352 358 12637914 10.1067/mjd.2003.105 (Pubitemid 36337071)
60. PM Schlievert LC Case KL Strandberg BB Abrams DY Leung 2008 Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis Clin Infect Dis 46 1562 1567 18419342 10.1086/586746 (Pubitemid 351720866)
61. H Lomholt KE Andersen M Kilian 2005 Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis J Invest Dermatol 125 977 982 16297199 1:CAS:528:DC%2BD2MXht1GrtrrO 10.1111/j.0022-202X.2005.23916.x
62. J Wehner K Neuber 2001 Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema Br J Dermatol 145 302 305 11531797 1:CAS:528:DC%2BD3MXmslyqsL0%3D 10.1046/j.1365-2133.2001. 04352.x (Pubitemid 32955360)
63. DY Leung R Harbeck P Bina, et al. 1993 Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens J Clin Invest 92 1374 1380 7690780 1:STN:280:DyaK3szovVyksg%3D%3D 10.1172/JCI116711 (Pubitemid 23273913)
64. E Sonkoly A Muller AI Lauerma, et al. 2006 IL-31: a new link between T cells and pruritus in atopic skin inflammation J Allergy Clin Immunol 117 411 417 16461142 1:CAS:528:DC%2BD28XhtlCktb4%3D 10.1016/j.jaci.2005.10.033 (Pubitemid 43192023)
65. KM Aberg MQ Man RL Gallo, et al. 2008 Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers J Invest Dermatol 128 917 925 17943185 1:CAS:528:DC%2BD1cXjtFOms70%3D 10.1038/sj.jid.5701099 (Pubitemid 351374295)
66. PY Ong T Ohtake C Brandt, et al. 2002 Endogenous antimicrobial peptides and skin infections in atopic dermatitis N Engl J Med 347 1151 1160 12374875 1:CAS:528:DC%2BD38XnslShsb0%3D 10.1056/NEJMoa021481
67. SJ Miller R Aly HR Shinefeld PM Elias 1988 In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids Arch Dermatol 124 209 215 3341800 1:STN:280:DyaL1c7jt12luw%3D%3D 10.1001/archderm.124.2.209 (Pubitemid 18054501)
68. DJ Bibel R Aly HR Shinefield 1992 Antimicrobial activity of sphingosines J Invest Dermatol 98 269 273 1545135 1:CAS:528:DyaK38XitlWksrw%3D 10.1111/1523-1747.ep12497842
69. I Nomura E Goleva MD Howell, et al. 2003 Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes J Immunol 171 3262 3269 12960356 1:CAS:528:DC%2BD3sXmvFGqu7c%3D (Pubitemid 37093553)
70. PM Elias Y Hatano ML Williams 2008 Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms J Allergy Clin Immunol 121 1337 1343 18329087 1:CAS:528:DC%2BD1cXmvV2ktLw%3D 10.1016/j.jaci.2008.01.022
71. PM Elias M Steinhoff 2008 "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis J Invest Dermatol 128 1067 1070 18408746 1:CAS:528:DC%2BD1cXksFyhtr0%3D 10.1038/jid.2008.88 (Pubitemid 351543225)
72. MJ Cork SG Danby Y Vasilopoulos, et al. 2009 Epidermal barrier dysfunction in atopic dermatitis J Invest Dermatol 129 1892 1908 19494826 1:CAS:528:DC%2BD1MXosFSksrs%3D 10.1038/jid.2009.133
73. MJ Cork DA Robinson Y Vasilopoulos, et al. 2006 New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions J Allergy Clin Immunol 118 3 21 16815133 1:CAS:528: DC%2BD28Xms1Gltb8%3D 10.1016/j.jaci.2006.04.042 quiz 22-3 (Pubitemid 43946484)
74. A Garg MM Chren LP Sands, et al. 2001 Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders Arch Dermatol 137 53 59 11176661 1:STN:280:DC%2BD3M7nsleiug%3D%3D (Pubitemid 32096358)
75. EH Choi MQ Man P Xu, et al. 2007 Stratum corneum acidification is impaired in moderately aged human and murine skin J Invest Dermatol 127 2847 2856 17554364 1:CAS:528:DC%2BD2sXhtlajsLbJ 10.1038/sj.jid.5700913 (Pubitemid 350134813)
76. EH Choi M Demerjian D Crumrine, et al. 2006 Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function Am J Physiol Regul Integr Comp Physiol 291 R1657 R1662 16857896 1:CAS:528:DC%2BD2sXktVGj 10.1152/ajpregu.00010.2006 (Pubitemid 44904132)
77. H Bisgaard A Simpson CN Palmer, et al. 2008 Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure PLoS Med 5 e131 18578563 10.1371/journal.pmed.0050131 1:CAS:528:DC%2BD1cXpvV2itLk%3D (Pubitemid 351919115)
78. SK Jeong HJ Kim JK Youm, et al. 2008 Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery J Invest Dermatol 128 1930 1939 18305573 1:CAS:528:DC%2BD1cXosVOmsb8%3D 10.1038/jid.2008.13 (Pubitemid 352001196)
79. N Novak H Baurecht T Schafer, et al. 2008 Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel J Invest Dermatol 128 1430 1435 18049447 1:CAS:528:DC%2BD1cXlvVSkt7s%3D 10.1038/sj.jid.5701190 (Pubitemid 351693185)
80. R Kurahashi Y Hatano K Katagiri 2008 IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo J Invest Dermatol 128 1329 1331 17960173 1:CAS:528:DC%2BD1cXksFyhsro%3D 10.1038/sj.jid.5701138 (Pubitemid 351543188)
81. Y Hatano H Terashi S Arakawa K Katagiri 2005 Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis J Invest Dermatol 124 786 792 15816837 1:CAS:528:DC%2BD2MXjsVagsr0%3D 10.1111/j.0022-202X.2005.23651.x (Pubitemid 40489506)
82. S Altrichter E Kriehuber J Moser, et al. 2008 Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis J Invest Dermatol 128 2232 2239 18480840 1:CAS:528:DC%2BD1cXpslWgtbY%3D 10.1038/jid.2008.80
83. Temeck J (2005) Protopic and Elidel presentation for FDA regulatory briefing on January 14, 2005
84. RS Stern 2006 Topical calcineurin inhibitors labeling: putting the "box" in perspective Arch Dermatol 142 1233 1235 16983018 10.1001/archderm.142.9.1233 (Pubitemid 44414414)
85. AB Fleischer Jr 2006 Black box warning for topical calcineurin inhibitors and the death of common sense Dermatol Online J 12 2 17083882
86. FM Arellano CE Wentworth A Arana C Fernandez CF Paul 2007 Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis J Invest Dermatol 127 808 816 17096020 1:CAS:528:DC%2BD2sXivVGls7g%3D 10.1038/sj.jid.5700622 (Pubitemid 46434650)
87. G Kameda C Kramm H Stege, et al. 2003 Unexpected high serum levels of tacrolimus after a single topical application in an infant J Pediatr 143 280 12970650 (Pubitemid 37082969)
88. A Allen E Siegfried R Silverman, et al. 2001 Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome Arch Dermatol 137 747 750 11405764 1:STN:280:DC%2BD3MzoslCgsw%3D%3D (Pubitemid 32577856)
89. DG Moskowitz AJ Fowler MB Heyman, et al. 2004 Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure J Pediatr 145 82 92 15238912 1:CAS:528:DC%2BD2cXlsVSgs7g%3D 10.1016/j.jpeds. 2004.03.052 (Pubitemid 38962457)
90. AS Paller LF Eichenfield RS Kirsner, et al. 2008 Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use Pediatrics 122 e1210 e1218 19015204 10.1542/peds.2008-1343
91. U Wahn JD Bos M Goodfield, et al. 2002 Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 e2 12093983 10.1542/peds.110.1.e2
92. J Ehrchen C Sunderkotter T Luger M Steinhoff 2008 Calcineurin inhibitors for the treatment of atopic dermatitis Expert Opin Pharmacother 9 3009 3023 19006475 1:CAS:528:DC%2BD1cXhtlKrtr3O 10.1517/14656560802498040
93. AB Jain LD Yee MA Nalesnik, et al. 1998 Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data Transplantation 66 1193 1200 9825817 1:STN:280:DyaK1M%2FktFWltg%3D%3D 10.1097/00007890-199811150-00014 (Pubitemid 28530324)
94. JR Hickey A Robson JN Barker CH Smith 2005 Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases Br J Dermatol 152 152 154 15656817 1:STN:280:DC%2BD2M%2FivF2ktQ%3D%3D 10.1111/j.1365-2133.2004.06280.x
95. BA Cook EM Warshaw 2009 Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy Am J Clin Dermatol 10 103 118 19222250 10.2165/00128071-200910020-00003
96. T Luger C Paul 2007 Potential new indications of topical calcineurin inhibitors Dermatology 215 Suppl 1 45 54 18174692 1:CAS:528: DC%2BD1cXit1WksA%3D%3D 10.1159/000102119 (Pubitemid 350308379)
97. LA Schachner C Lamerson MP Sheehan, et al. 2005 Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study Pediatrics 116 e334 e342 16140675 10.1542/peds.2004- 2638 (Pubitemid 44336646)
98. A Paller LF Eichenfield DY Leung D Stewart M Appell 2001 A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients J Am Acad Dermatol 44 S47 S57 11145795 1:STN:280:DC%2BD3M7itVeltA%3D%3D
99. M Kim M Jung SP Hong, et al. 2009 Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function Exp Dermatol 19 501 510 19703225 10.1111/j.1600-0625.2009. 00941.x 1:CAS:528:DC%2BC3cXovVKmsrY%3D
100. M Rodriguez-Martin M Hupe M Man J Naya P Elias 2009 Topical imiquimod and calcipotriol stimulate antimicrobial peptide expression in mouse epidermis J Invest Dermatol 129 S72
101. N Goksugur B Ozbostanci SB Goksugur 2007 Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba Pediatr Dermatol 24 E63 E65 17958783 10.1111/j.1525-1470.2007.00443.x (Pubitemid 47631916)
102. KA Papp T Werfel R Folster-Holst, et al. 2005 Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study J Am Acad Dermatol 52 240 246 15692468 10.1016/j.jaad.2004.09.016
103. S Segura D Romero C Carrera P Iranzo T Estrach 2005 Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream Acta Derm Venereol 85 524 525 16396803 (Pubitemid 43087293)
104. TG Berger M Duvic AS Van Voorhees MJ VanBeek IJ Frieden 2006 The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force J Am Acad Dermatol 54 818 823 16635663 10.1016/j.jaad.2006.01.054
105. RG Langley TA Luger MJ Cork D Schneider C Paul 2007 An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials to post-marketing surveillance Dermatology 215 Suppl 1 27 44 18174691 1:CAS:528:DC%2BD1cXit1Wksg%3D%3D 10.1159/000102118 (Pubitemid 350308378)
106. JS Kao JW Fluhr MQ Man, et al. 2003 Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities J Invest Dermatol 120 456 464 12603860 1:CAS:528:DC%2BD3sXitlOhtL8%3D 10.1046/j.1523-1747.2003.12053.x (Pubitemid 36298433)
107. PM Elias 2008 Barrier-repair therapy for atopic dermatitis: corrective lipid biochemical therapy Exp Rev Dermatol 3 441 452 1:CAS:528: DC%2BD1cXpt1altbc%3D 10.1586/17469872.3.4.441
108. PY Ong 2009 Emerging drugs for atopic dermatitis Expert Opin Emerg Drugs 14 165 179 19216704 1:CAS:528:DC%2BD1MXivFSmur8%3D 10.1517/14728210902721248
109. R Voegeli AV Rawlings M Breternitz, et al. 2009 Increased stratum corneum serine protease activity in acute eczematous atopic skin Br J Dermatol 161 70 77 19416247 1:CAS:528:DC%2BD1MXpsVeisrw%3D 10.1111/j.1365-2133.2009.09142.x
110. PM Elias M Schmuth 2009 Abnormal skin barrier in the etiopathogenesis of atopic dermatitis Curr Opin Allergy Clin Immunol 9 437 446 19550302 1:CAS:528:DC%2BD1MXhtVSms7fI 10.1097/ACI.0b013e32832e7d36
111. MJ Cork J Britton L Butler, et al. 2003 Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse Br J Dermatol 149 582 589 14510993 1:STN:280:DC%2BD3svpslGhtw%3D%3D 10.1046/j.1365-2133.2003.05595.x (Pubitemid 37281592)
112. Elias PM (2006) Epilogue: fixing the barrier-theory and rational deployment. In: Elias PM, Feingold KR (eds) Skin barrier. Taylor & Francis, New York, pp 591-600
113. J Sugarman L Parish 2009 Efficacy of a lipid-based, barrier repair formulation in moderate-to-severe pediatric atopic dermatitis J Drugs Dermatol 8 1106 1111 20027938
114. Simpson E, Berry T, Tofte S, Hanifin JM, Eichenfield L (2008) EpiCeram for the treatment of mild-to-moderate atopic dermatitis-a pilot study. IID 2008 Kyoto, Japan
115. Y Hatano MQ Man Y Uchida, et al. 2010 Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators J Allergy Clin Immunol 125 160-9 e1 e5 19818482
116. Y Hatano MQ Man Y Uchida, et al. 2009 Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis J Invest Dermatol 129 1824 1835 19177139 1:CAS:528:DC%2BD1MXntFCis7w%3D 10.1038/jid.2008.444
117. SJ Galli M Tsai AM Piliponsky 2008 The development of allergic inflammation Nature 454 445 454 18650915 1:CAS:528:DC%2BD1cXovV2mtbs%3D 10.1038/nature07204
118. A De Benedetto CM Qualia FM Baroody LA Beck 2008 Filaggrin expression in oral, nasal, and esophageal mucosa J Invest Dermatol 128 1594 1597 18172455 10.1038/sj.jid.5701208 1:CAS:528:DC%2BD1cXlvVSktLY%3D (Pubitemid 351693198)